Testosterone Therapy and Prostate Health: PSA Monitoring Explained
Written by the Innovative Men's Health Editorial Team
Medically reviewed by Alessa Lopez-Castor, ARNP, DNP
Last medically reviewed: September 18, 2026
If you are researching TRT and prostate health, the question that often comes first is how PSA monitoring fits into testosterone replacement therapy. This educational guide explains prostate-specific antigen in plain language, baseline and follow-up themes aligned with Endocrine Society and American Urological Association guidance, shared decision-making, and when a urology referral may be discussed.
This page does not claim that testosterone therapy causes or prevents prostate cancer. It does not diagnose you, recommend dosing, or replace a medical evaluation. Inquiry does not equal a prescription. Results vary. A no-pressure consultation is appropriate anytime you want individualized answers.
What PSA is — and what a single number is not
MedlinePlus describes PSA as a protein made by the prostate. A PSA blood test measures the amount in your blood. It is commonly used to help screen for prostate cancer, evaluate prostate symptoms, or monitor known prostate conditions — but a screening test cannot diagnose cancer by itself.
Important themes include:
A higher PSA may raise concern, but non-cancer conditions such as an enlarged prostate, prostatitis, urinary infection, recent ejaculation, or certain procedures can also raise it.
It is possible to have a higher PSA without cancer or a lower PSA with cancer.
Preparation may include avoiding ejaculation for about 24 hours before the draw and telling your provider about medicines that can affect results. Do not stop medicines unless your clinician tells you to.
A single PSA number is a data point for clinician interpretation alongside age, risk factors, symptoms, exam findings, and trends over time — not a do-it-yourself cancer verdict.
Prostate health before TRT: shared decision, not scare tactics
Prostate monitoring during testosterone therapy is framed as shared decision-making, not one-size-fits-all panic or false reassurance.
AUA testosterone-deficiency guidance states that PSA should be measured in men over 40 before starting testosterone therapy to reduce the chance of beginning treatment in someone with unrecognized prostate cancer. If a baseline PSA is newly elevated, repeating the test and completing a more formal evaluation before therapy may be appropriate. The AUA also states clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate cancer. That is not the same as claiming TRT prevents cancer.
Endocrine Society guidance recommends against starting testosterone therapy in men with prostate cancer, a palpable prostate nodule or induration, PSA above 4 ng/mL, or PSA above 3 ng/mL in men at increased prostate-cancer risk without further urological evaluation. These numbers are guideline context for clinicians, not self-diagnosis cutoffs.
For hypogonadal men ages 55 to 69 being considered for testosterone therapy, with life expectancy over 10 years, the Endocrine Society suggests discussing prostate-cancer risk evaluation and monitoring through shared decision-making. For men ages 40 to 69 at increased risk, discussion and offering monitoring options are also suggested. When monitoring is chosen, assessment before starting and again 3 to 12 months afterward is part of that framework.
Follow-up PSA during TRT
Once therapy is underway, prostate monitoring remains clinician-directed. For patients who choose prostate monitoring, the Endocrine Society generally frames prostate-cancer risk assessment before starting testosterone and again 3 to 12 months after starting. After the first year, monitoring generally follows standard prostate-cancer screening guidance based on age and risk.
For men without a history of prostate cancer who maintain on-treatment testosterone levels in a therapeutic range, AUA guidance frames ongoing PSA testing through shared decision-making aligned with early-detection recommendations. Clinicians may choose more frequent testing in selected situations; this is clinical judgment, not a do-it-yourself calendar.
This page intentionally stays focused on prostate and PSA safety. Broader follow-up labs — including testosterone levels, hematocrit, and the full monitoring picture — belong in separate education. Ask your clinician how PSA fits your overall plan.
When urology referral may be discussed
Referral is about appropriate specialty evaluation, not assuming a cancer diagnosis from a blog. During the first 12 months of testosterone treatment, Endocrine Society guidance recommends urological consultation for:
A confirmed PSA increase greater than 1.4 ng/mL above baseline.
A confirmed PSA greater than 4.0 ng/mL.
A prostatic abnormality detected on digital rectal examination.
Other practical reasons to contact your clinician promptly include substantial worsening of lower urinary tract symptoms, a new prostate-nodule concern, or unexplained urinary symptoms. These published figures are clinician referral triggers — not a checklist for diagnosing yourself.
If PSA is higher than expected, next steps may include repeating PSA, an exam, urine testing for infection, imaging in some pathways, or biopsy when clinically indicated. Only biopsy diagnoses cancer. Your licensed medical provider decides the sequence.
What this article does not claim
It does not claim testosterone therapy causes prostate cancer.
It does not claim testosterone therapy prevents prostate cancer.
It does not interpret your personal PSA result.
It does not provide dosing, product brands, or self-directed therapy changes.
Men with a history of prostate cancer need individualized specialist discussion. Evidence to quantify the risk-benefit of testosterone in that setting remains inadequate, so decisions are specialist-led.
Care at IMHS Bellevue — and eligible Washington telehealth
At Innovative Men's Health, prostate and PSA themes are part of evaluation-first testosterone therapy conversations when age- or risk-appropriate.
Innovative Men's Health is at 1940 116th Ave NE Unit 201, Bellevue, WA 98004; phone (425) 455-1700. Eligible Washington adults may use telehealth for appropriate consultations. Results vary; treatment is individualized when clinically appropriate. Contact does not guarantee therapy, specific PSA results, or any other outcome.
Key takeaways
PSA is a prostate-produced blood marker; it does not diagnose cancer by itself, and non-cancer conditions can raise it.
AUA guidance calls for PSA measurement in men over 40 before starting testosterone and notes the absence of evidence linking TRT to the development of prostate cancer — not a prevention claim.
When prostate monitoring is chosen, Endocrine Society guidance frames assessment before TRT and again 3 to 12 months after starting.
First-year urology-referral triggers include a confirmed PSA rise greater than 1.4 ng/mL above baseline, a confirmed PSA above 4.0 ng/mL, or a prostate abnormality on examination.
No dosing or outcome guarantees are provided; monitoring is individualized.
Frequently asked questions
Does testosterone therapy cause prostate cancer?
This article does not claim that. The AUA states clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate cancer. Absence of evidence of causation is not proof of prevention. Discuss your personal risk with your clinician.
Do I need a PSA test before starting TRT?
AUA guidance states that PSA should be measured in men over 40 before starting testosterone therapy. Endocrine Society guidance also describes situations where further urologic evaluation is needed before therapy. Your clinician personalizes the plan.
How often is PSA checked after starting TRT?
When monitoring is chosen, Endocrine Society guidance frames reassessment 3 to 12 months after starting, then age- and risk-appropriate screening thereafter. Your clinician sets the timing.
Does a rising PSA during TRT mean I have cancer?
Not by itself. Confirmed changes may trigger urology referral for appropriate evaluation, not self-diagnosis. Trends, repeat testing, symptoms, and clinical context matter.
Can prostate and PSA questions be discussed by telehealth?
Eligible Washington adults may use Washington telehealth for appropriate consultations; laboratory draws and physical examinations still follow clinician orders.
Keep reading
Next step
Care is available in Bellevue at Unit 201 and, for eligible patients, through Washington telehealth. Evaluation is required; results vary; this page does not guarantee PSA results, therapy eligibility, or any other outcome.
Sources
Disclaimer
This article is for educational purposes only and does not provide medical advice, diagnosis, or treatment. It does not establish a provider–patient relationship. Always consult a licensed medical provider about testosterone therapy, PSA testing, prostate evaluation, and care options. Innovative Men's Health does not diagnose readers from this page and does not guarantee PSA results, therapy eligibility, symptom improvement, or any other outcome. This page does not claim that testosterone therapy causes or prevents prostate cancer. PSA figures appear only as published guideline context for clinician-directed shared decision-making and referral — not do-it-yourself cancer diagnosis or home laboratory interpretation. No dosing regimens, product brands, or self-directed therapy changes are provided. Individual results vary; evaluation is required; inquiry does not equal a prescription; treatment is individualized when clinically appropriate.
Comments